Overview
- In a randomized NYU Langone emergency-department trial (n=69, ages 18–65), 82.4% of RELAXaHEAD users achieved a ≥5-point MIDAS improvement versus 45.7% in a diary-only control.
- The intervention delivers progressive muscle relaxation exercises via smartphone to target migraine-related disability.
- Investigators reported a dose-response pattern, with more frequent PMR sessions associated with greater disability gains.
- Across the study period, monthly headache-day counts did not differ significantly between the app and control groups.
- Authors disclosed financial interests in the app’s intellectual property, licensed to CareTurner, and a larger NIH-funded primary care trial is underway to test broader effectiveness.